Drugs / MP-376
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00739648 | Oct 2008 → Jan 2010 | chronic obstructive pulmonary disease | Amgen | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT01270347 | Jan 2011 → Oct 2012 | cystic fibrosis | Amgen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MP-376 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00739648 ↗ |
| Known as | Levofloxacin | “MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment” NCT01270347 ↗ |
| Route | Inhaled | “MP-376 240 mg BID inhaled via the PARI eFlow nebulizer” NCT00739648 ↗ |